Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 1:13:1165013.
doi: 10.3389/fonc.2023.1165013. eCollection 2023.

Editorial: Case reports in renal cell carcinoma

Tony Z Zhuang  1 , Seema M Mustafa  1 , Kathryn E Beckermann  2 , Mehmet Asim Bilen  3
Affiliations
Editorial

Editorial: Case reports in renal cell carcinoma

Tony Z Zhuang et al. Front Oncol. .
No abstract available

Keywords: biomarker; cytoreduction; immunotherapy; next-generation sequencing; renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

MB has acted as a paid consultant for and/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi, and his institution has received grants from Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer for work performed outside of the current study. KB has acted as a paid consultant for and/or as a member of the advisory boards of LCFA-BMS-IASLC for Young Investigator Award, Alpine Biosciences, Aravive, Astrazeneca, Aveo, BMS, Exelexis, Merck, Sanofi, and Seagen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Case reports in renal cell carcinoma

References

    1. American Cancer Society . Key statistics about kidney cancer 2023 (2023). Available at: https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html.
    1. Motzer RJ, Tannir M, McDermott DF, Fontera OA, Melichar B, Choueiri TK, et al. . Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New Engl J Med (2018) 378:1277–1290. doi: 10.1056/NEJMoa1712126 - DOI - PMC - PubMed
    1. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. . Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med (2021) 384(9):829–41. doi: 10.1056/NEJMoa2026982 - DOI - PMC - PubMed
    1. Lee C-H, Shah AY, Rasco D, Rao A, Taylor MH, Simone CD, et al. . Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): A phase 1b/2 study. Lancet Oncol (2021) 22(7):946–58. doi: 10.1016/S1470-2045(21)00241-2 - DOI - PMC - PubMed
    1. Rini BI, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, et al. . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. (2021), Wolters Kluwer Health.

Publication types

LinkOut - more resources